Systemic lupus erythematosus trials recruiting in Maryland

All Systemic lupus erythematosus trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · Maryland: Rockville
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
  NCT07430306 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Silver Spring
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Maryland: Bethesda
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
  NCT06133972 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
  NCT00198068 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · Maryland: Baltimore
• Study of Systemic Lupus Erythematosus
  NCT00001372 · Phase: Not specified · Ages: 3 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
  NCT05440422 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Maryland: Bethesda